Dermata Therapeutics, Inc. DRMAW
0.00 USD 0.00 (-50.00%)
Aug 17, 2026, 11:53 AM EDT
0.0005 Day range 0.0011
0.0005 52-week range 0.0011
- YTD
- -96.81%
- 1 year
- -96.81%
News
benzinga.com Dermata Therapeutics Secures Australian Patent Acceptance For Bioneedle System In Dermal Fillers - This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers -- The Company also has allowed and issued patents in the US,…
benzinga.com Dermata Therapeutics Announces Private Placement Up To $12.4M Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced that it has entered into definitive agreements…
benzinga.com Dermata Therapeutics Announces Australian Patent Office Accept Patent Application For Spongilla Technology Combination As Method For Treating Acne - This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to topically treat acne -- Dermata expects to launch a new once-weekly,…
benzinga.com Dermata Therapeutics Announces Strategic Pivot To Prioritize Development And Distribution Of OTC Pharmaceutical Dermatology Focused Products Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced a bold strategic pivot to prioritize the…
benzinga.com Dermata's XYNGARI Phase 3 Trial Hits Statistically Significant Difference At 4 Weeks - Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -- Additional data analysis revealed that…